Free Trial
NASDAQ:DYN

Dyne Therapeutics Q3 2023 Earnings Report

Dyne Therapeutics logo
$11.90 +0.14 (+1.19%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$11.62 -0.28 (-2.39%)
As of 08:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dyne Therapeutics EPS Results

Actual EPS
-$0.99
Consensus EPS
-$0.83
Beat/Miss
Missed by -$0.16
One Year Ago EPS
N/A

Dyne Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Dyne Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Monday, October 30, 2023
Conference Call Time
8:00AM ET

Upcoming Earnings

Dyne Therapeutics' Q1 2025 earnings is scheduled for Monday, August 11, 2025

Dyne Therapeutics Earnings Headlines

This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.
See More Dyne Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dyne Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dyne Therapeutics and other key companies, straight to your email.

About Dyne Therapeutics

Dyne Therapeutics (NASDAQ:DYN), a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

View Dyne Therapeutics Profile

More Earnings Resources from MarketBeat